Pulmonx (LUNG)

• Market cap: $58.7M
• 1 day: -6.08%
• 5 days: -21.02%
• 1 month: -2.11%
• 3 months: -46.54%
• 6 months: -17.75%
• Year to date: -39.57%
• 1 year: -82.11%
• 5 years: -97.37%
• 10 years: -96.46%
• Sector: Healthcare
• Industry: Medical Devices

About: Pulmonx Corpa is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution, comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The company has a single reportable and operating segment structure. Geographically in the USA, Europe, the Middle East, and Africa (EMEA), Asia Pacific, and Other International, with the majority of revenue from the USA.

Employees: 296